Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility

Martine C. Ploem, Noor A.A. Giesbertz, Annelien L. Bredenoord, Valesca P. Retèl*, Wim H. van Harten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

107 Downloads (Pure)


Tumour DNA and germline testing, based on DNA-wide sequencing analysis, are becoming more and more routine in clinical-oncology practice. A promising step in medicine, but at the same time leading to challenging ethicolegal questions. An important one is under what conditions individuals (patients and their relatives, research participants) should be recontacted with new information, even if many years have passed since the last contact. Based on legal- and ethical study, we developed a tool to help professionals to decide whether or not to recontact an individual in specific cases. It is based on four assessment criteria: (1) professional relationship (2) clinical impact (3) individual's preferences and (4) feasibility. The tool could also serve as a framework for guidelines on the topic.

Original languageEnglish
Pages (from-to)22-26
Number of pages5
JournalEuropean Journal of Cancer
Publication statusPublished - Jun 2023

Bibliographical note

Funding Information:
This study was performed as a part of the “Technology Assessment of Next Generation Sequencing in Personalized Oncology ( TANGO )” project, funded by ZonMW , (The Netherlands Organisation for Health Research and Development) #846001002 .

Publisher Copyright:
© 2023 The Authors


Dive into the research topics of 'Duty to recontact in genomic cancer care: A tool helping to assess the professional's responsibility'. Together they form a unique fingerprint.

Cite this